Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
Clinical Pharmacology and Therapeutics
|
December 17, 2016
National Cancer Institute Formulary: A Public-Private Partnership Providing Investigators Access to Investigational Anticancer Agents
J V Cristofaro, S S Ansher, J A Zwiebel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2014
The role of age on dose-limiting toxicities in phase I dose-escalation trials
A Schwandt, P J Harris, S Hunsberger, et al.
Anticancer Research
|
April 19, 2000
Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs
S Martin-Aragon, S K Mukherjee, B J Taylor, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 1, 1987
Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas
C R Fairchild, S P Ivy, T Rushmore, et al.
Gynecologic Oncology
|
April 22, 2015
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia
H Hirte, S Lheureux, G F Fleming, et al.
The Journal of Biological Chemistry
|
December 15, 1988
Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line
S P Ivy, A Tulpule, C R Fairchild, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2001
Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days
A Dowlati, C L Hoppel, S T Ingalls, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
November 1, 2001
New targets for cancer chemotherapy
S G Arbuck, J Dancey, J M Pluda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 29, 2003
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors
S Goel, A Bulgaru, H Hochster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2010
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
J J Biagi, A M Oza, H I Chalchal, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
Clinical Pharmacology and Therapeutics
|
December 17, 2016
National Cancer Institute Formulary: A Public-Private Partnership Providing Investigators Access to Investigational Anticancer Agents
J V Cristofaro, S S Ansher, J A Zwiebel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2014
The role of age on dose-limiting toxicities in phase I dose-escalation trials
A Schwandt, P J Harris, S Hunsberger, et al.
Anticancer Research
|
April 19, 2000
Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs
S Martin-Aragon, S K Mukherjee, B J Taylor, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 1, 1987
Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas
C R Fairchild, S P Ivy, T Rushmore, et al.
Gynecologic Oncology
|
April 22, 2015
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia
H Hirte, S Lheureux, G F Fleming, et al.
The Journal of Biological Chemistry
|
December 15, 1988
Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line
S P Ivy, A Tulpule, C R Fairchild, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2001
Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days
A Dowlati, C L Hoppel, S T Ingalls, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
November 1, 2001
New targets for cancer chemotherapy
S G Arbuck, J Dancey, J M Pluda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 29, 2003
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors
S Goel, A Bulgaru, H Hochster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2010
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
J J Biagi, A M Oza, H I Chalchal, et al.
Page
of 4